Special Issue "Research in Aggressive Brain Tumors: Biology and Precision Therapy"
Deadline for manuscript submissions: closed (31 December 2021).
Comprehensive Cancer Center-Central Nervous System Tumors Unit, Medical University Vienna, 1090 Vienna, Austria
Interests: brain tumor; glioblastoma; ependymoma; targeted therapy; heterogeneity; biomarker; resistance; oncogenic driver
Primary brain tumors affect both children and adults and represent a substantial source of morbidity and mortality worldwide. Among the adult population, glioblastoma is the most common malignant histological type, characterized by a dismal prognosis of less than 2 years, despite multidisciplinary treatment that includes surgical resection and combined radio- chemotherapy. In children, brain tumors including medulloblastoma, gliomas, and ependymomas, rank first among all solid cancers. Survival rates strongly depend on tumor grading and therapeutic options, which are often limited in pediatric patients.
During the last decade, comprehensive genomics and epigenomics studies based on bulk or single-cell omics technologies have elucidated new aspects of molecular alterations and inter-tumor and intra-tumor heterogeneity. These findings improved diagnosis and led to the discovery of new brain tumor subtypes with distinct molecular alterations. Thus, targeted therapies, including MEK and BRAF V600E inhibitors, have been implemented in treatment regimens of pediatric and adult brain tumor patients. However their efficacy is limited due to the presence of multiple genetic abnormalities, limited transport via the blood–brain barrier, intrinsic or acquired resistance mechanisms, or unacceptable side-effects.
This Special Issue will bring the knowledge of genetic, epigenetic, developmental, and microenvironmental heterogeneity into a (pre)clinically relevant context for aggressive pediatric and adult brain tumors
Dr. Daniela Lötsch
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- brain tumor
- targeted therapy